

*This article has been accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading processes, that may lead to differences between this version and the version of record.*

*Please cite this article as <https://doi.org/10.4097/kja.24089>*

Epub ahead of print

**Effect of perioperative intravenous ibuprofen versus acetaminophen on postoperative opioid consumption and pain after general anesthesia: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials**

Sung Hye Kim, Hyun Kang, In-Jung Jun, Hye Won Park, Byung Hoon Yoo, Yun-Hee Lim, Kye-Min Kim

[Author information]

Sung Hye Kim, M.D.

Department of Anesthesiology and Pain Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea

ORCID: <https://orcid.org/0009-0004-6814-4761>

Hyun Kang, M.D., Ph.D.

Department of Anesthesiology and Pain Medicine, Chung-Ang University College of Medicine, Seoul, Korea

ORCID: <https://orcid.org/0000-0003-2844-5880>

In-Jung Jun, M.D. Ph.D.

Department of Anesthesiology and Pain Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea

ORCID: <https://orcid.org/0000-0003-1386-3940>

Hye Won Park

Inje University Medical Library, Busan, Korea.

ORCID: <https://orcid.org/0000-0001-9374-7848>

Byung Hoon Yoo, M.D., Ph.D

Department of Anesthesiology and Pain Medicine, Inje University Sanggye Paik Hospital, Seoul,  
Korea

ORCID: <https://orcid.org/0000-0002-1958-8380>

Yun-Hee Lim M.D., Ph.D

Department of Anesthesiology and Pain Medicine, Inje University Sanggye Paik Hospital, Seoul,  
Korea

ORCID: <https://orcid.org/0000-0003-2399-4768>

Kye-Min Kim, M.D., Ph.D.

Department of Anesthesiology and Pain Medicine, Inje University Sanggye Paik Hospital, Seoul,  
Korea

ORCID: <https://orcid.org/0000-0003-1298-7642>

[Running title]

IV ibuprofen vs. acetaminophen for pain

[Corresponding author]:

Kye-Min Kim, M.D., Ph.D.

Department of Anesthesiology and Pain Medicine, Inje University Sanggye Paik Hospital,

Dongil-ro 1342, Nowon-gu, Seoul 01757, Korea

Tel: +82-2-950-1168

Fax: +82-2-950-1323

Email: [kyemin@paik.ac.kr](mailto:kyemin@paik.ac.kr)

ORCID: <https://orcid.org/0000-0003-1298-7642>

[Previous presentation in conferences]: Not applicable.

[Conflict of Interest]: No potential conflict of interest relevant to this article was reported.

[Funding]: Not applicable.

[Acknowledgments]: Not applicable.

[IRB number]: Not applicable.

[Clinical trial registration number]:

PROSERO; <https://www.crd.york.ac.uk/PROSPERO>, no. [CRD42023429275](https://www.crd.york.ac.uk/PROSPERO)

## **Author Contributions**

Conceptualization: Sung Hye Kim, Kye-Min Kim

Study design: Sung Hye Kim, In-Jung Jun, Kye-Min Kim

Data acquisition: Sung Hye Kim, Hye Won Park, Kye-Min Kim

Analysis and interpretation of data: Sung Hye Kim, Hyun Kang, Kye-Min Kim

Writing—original draft: Sung Hye Kim, Hyun Kang, Kye-Min Kim

Writing—review & editing: Sung Hye Kim, Hyun Kang, Hye Won Park, In-Jung Jun, Byung Hoon

Yoo, Yun-Hee Lim, Kye-Min Kim,

Epub ahead of print

**Effect of perioperative intravenous ibuprofen versus acetaminophen on postoperative opioid consumption and pain after general anesthesia: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials**

[Author Names]

[Author affiliations]

**Running title:** IV ibuprofen vs. acetaminophen for pain

**Corresponding author:**

**Previous presentation in conferences:** Not applicable

**Conflict of interest:** No potential conflict of interest relevant to this article was reported.

**Funding:** Not applicable

**Acknowledgments:** Not applicable

**IRB number:**

**Clinical trial registration number:** PROSPERO; no. CRD42023429275

1     **Effect of perioperative intravenous ibuprofen versus acetaminophen on postoperative opioid**  
2 **consumption and pain after general anesthesia: a systematic review and meta-analysis with trial**  
3                   **sequential analysis of randomized controlled trials**

4

5

6                   **Running title: IV ibuprofen vs. acetaminophen for pain**

7

Epub ahead of print

## Abstract

**Background:** Ibuprofen and acetaminophen are widely used as adjuvant analgesics for postoperative pain. This meta-analysis compared the effects of intravenous (IV) ibuprofen and acetaminophen on postoperative opioid consumption and pain intensity after general anesthesia.

**Methods:** PubMed/MEDLINE, EMBASE, and Cochrane Library databases were searched to identify relevant studies published up to May 2023. Randomized controlled trials (RCTs) comparing the effects of perioperative IV ibuprofen and acetaminophen on postoperative opioid consumption and pain after general anesthesia were included in the meta-analysis and trial sequential analysis (TSA).

**Results:** Eight studies with 494 participants were included. Compared to IV acetaminophen, IV ibuprofen significantly reduced 24 h opioid consumption, presented as morphine equivalents (mean difference [MD]: -6.01 mg, 95% CI [-8.60, -3.42],  $P < 0.00001$ ,  $I^2 = 55\%$ ), and pain scores (on a scale of 0–10) at 4–6 h (MD: -0.83, 95% CI [-1.29, -0.37],  $P = 0.0004$ ,  $I^2 = 65\%$ ) and 12 h (MD: -0.38, 95% CI [-0.68, -0.08],  $P = 0.01$ ,  $I^2 = 11\%$ ) postoperatively. These results were statistically significant in TSA. Pain scores at 24 h postoperatively and side effects were not significantly different between the two groups in the meta-analysis, and TSA revealed that the sample size was too small to adequately evaluate the effects, requiring further studies for conclusive results.

**Conclusions:** Perioperative IV ibuprofen reduced 24 h opioid consumption and pain severity up to 12 h postoperatively compared to acetaminophen. Additional research is required to assess pain intensity beyond 12 h and side effects.

**Keywords:** Acetaminophen; General anesthesia; Ibuprofen; Meta-analysis; Opioid analgesics; Postoperative pain.



## 1 **Introduction**

2 Postoperative pain management can affect the clinical outcomes and patient satisfaction after surgery [1].  
3 While opioids traditionally play a crucial role in postoperative pain relief, there is an increasing tendency  
4 to minimize their usage owing to concerns regarding adverse effects and the risk of addiction [2,3]. In  
5 the same context, multimodal analgesia has become a standard practice for postoperative pain control,  
6 with acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) gaining popularity as  
7 adjunctive analgesics [4-6].

8 Acetaminophen (paracetamol) and NSAIDs exert their analgesic effects via different mechanisms.  
9 Acetaminophen primarily acts centrally by inhibiting the synthesis of prostaglandins via the  
10 cyclooxygenase (COX) pathway in the central nervous system, thereby exhibiting analgesic and  
11 antipyretic effects [7]. In contrast, NSAIDs have a peripheral effect by inhibiting both COX-1 and COX-  
12 2 enzymes, reducing the production of prostaglandins in damaged tissues, and showing analgesic, anti-  
13 inflammatory, and antipyretic effects [8]. Among the various types of NSAIDs, ibuprofen, a propionic  
14 acid derivative, has been preferred for its less unwanted adverse effects because of the low COX-1:COX-  
15 2 inhibition ratio [9].

16 Both acetaminophen and ibuprofen have been proven effective and safe for the treatment of  
17 postoperative pain since the introduction of their intravenous (IV) forms [10,11]. However, the results  
18 regarding which drug is more effective are inconsistent [12,13].

19 The aim of this meta-analysis with trial sequential analysis (TSA) of randomized controlled trials  
20 (RCTs) is to comprehensively evaluate and compare the effect of IV ibuprofen and IV acetaminophen  
21 on postoperative opioid consumption and pain after general anesthesia.

22

## 1 **Materials and methods**

### 2 ***Study design***

3 This systematic review and meta-analysis was designed in accordance with the ‘Preferred Reporting  
4 Items for Systematic Reviews and Meta-Analyses’ guidelines (Supplement 1). This review was  
5 registered with the ‘International Prospective Register of Systematic Reviews’ (PROSPERO;  
6 <https://www.crd.york.ac.uk/PROSPERO>, no. [CRD42023429275](https://www.crd.york.ac.uk/PROSPERO))

7

### 8 ***Information sources and search strategy***

9 A literature search was conducted using the PubMed/MEDLINE, EMBASE, and Cochrane Library  
10 electronic databases. The search strategies were established by a librarian with extensive experience in  
11 searching for systematic reviews. The search terms included variants of terms, such as ‘intravenous,’  
12 ‘parenteral,’ ‘administration,’ ‘ibuprofen,’ ‘acetaminophen,’ ‘postoperative pain,’ ‘opioid,’ ‘morphine,’  
13 ‘fentanyl,’ ‘analgesia,’ and ‘patient-controlled analgesia,’ as well as Medical Subject Heading (MeSH)  
14 or EMBASE Subject Heading (EMTREE) terms (Supplement 1). The search was limited to RCTs  
15 conducted in humans. There were no restrictions on publication year or language. Grey literature was not  
16 excluded. The final search was completed on May 23, 2023.

17

### 18 ***Study selection and eligibility criteria***

19 Duplicates were removed after completing the literature search. Primary selection, based on titles and  
20 abstracts, was performed independently by two authors (KM and SH). For the final selection, the full  
21 texts of the first selection studies were independently assessed for eligibility by two authors (KM and  
22 SH). Any disagreements between the two authors were resolved through discussion with a third reviewer.

23 The inclusion criteria of this meta-analysis were as follows: (1) patients under general anesthesia; (2)

1 adult patients; (3) studies comparing IV ibuprofen and IV acetaminophen; (4) perioperative  
2 administration of ibuprofen or acetaminophen; (5) appropriate postoperative outcomes (pain scores or  
3 opioid consumption) should be presented; and (6) the type of study should be RCTs.

4 There were no restrictions on the dosage frequency of ibuprofen or acetaminophen.

5 The exclusion criteria were as follows: (1) non-human studies, (2) type of anesthesia other than general  
6 anesthesia (e.g., local anesthesia, regional anesthesia, and sedation and analgesia), (3) pediatric or  
7 neonatal patients, (4) non-RCTs, (5) no appropriate postoperative outcomes, (6) non-IV administration  
8 of ibuprofen or acetaminophen, and (7) no comparison between ibuprofen and acetaminophen.

9

#### 10 ***Data extraction***

11 Two authors (KM and SH) independently extracted data from the text, tables, and graphs presented in  
12 each paper and confirmed that there was no missing or incorrect information. The collected information  
13 included the authors' name, publication year, study design, type of surgery, patient characteristics, dose  
14 of intervention drug, intervention method (such as the number of dosing and interval), and postoperative  
15 outcomes. Postoperative outcomes included 24 h cumulative opioid consumption, postoperative pain  
16 scores, side effects, and rescue analgesics.

17 The mean and standard deviation (SD) of 24 h opioid consumption and pain scores upon recovery  
18 from anesthesia, at 4–6 h, 12 h, and 24 h postoperatively were extracted. Pain scores at recovery included  
19 scores from emergence from anesthesia until 30 min after surgery. Regarding pain scores at 4–6 h  
20 postoperatively, priority was given to the scores at 6 h. If data were not available at 6 h, the data measured  
21 at 4 h were used as replacements. Pain was assessed using visual analog scale (VAS) scores and expressed  
22 on a scale of 0–10 in all studies except for one that used a scale of 0–100 [14]. In the present meta-  
23 analysis, pain scores were shown on a scale of 1–10.

1 When outcome data were presented as medians with interquartile ranges [15], the sample mean and  
2 SD were estimated using the Box-Cox method recommended by McGrath et al. [16]. In cases where data  
3 were presented as graphs [13], two authors independently measured the values from the graphs, and the  
4 mean values from their measurements were used for the meta-analysis. When only the mean value was  
5 provided [13], the SD was estimated using the RevMan calculator (available at  
6 <https://training.cochrane.org/resource/revman-calculator>).

7 In addition, data on the number of patients experiencing adverse effects and the use of rescue  
8 analgesics were collected. For nausea and vomiting, only studies that separately reported the incidence  
9 of nausea or vomiting were included in the meta-analysis. When the results of the studies were  
10 insufficient or unclear, the study authors were contacted via email.

11

### 12 ***Risk of bias (ROB) assessment***

13 In this meta-analysis, the quality of the studies was evaluated using the ROB 2.0 tool recommended by  
14 Cochrane for assessing the quality of randomized trials. Two authors (KM and SH) independently  
15 performed the evaluations. In cases of disagreements, a third author (H) was involved to resolve them.  
16 The ROB for a specific outcome was evaluated across five distinct domains: randomization process  
17 (domain 1), deviations from intended interventions (domain 2), missing outcome data (domain 3),  
18 measurement of the outcome (domain 4), and selection of the reported result (domain 5). Within each  
19 domain, responses to signaling questions determined the evaluations of 'low risk of bias,' 'some  
20 concerns,' or 'high risk of bias' [17]. Following the assessments across these five domains, the overall  
21 ROB for the specific outcome was determined.

22 The inter-rater reliability of the assessment of ROB was evaluated using Cohen's kappa, and its values  
23 were interpreted as follows: 0–0.20 indicating no agreement, 0.21–0.39 as minimal, 0.40–0.59 as weak,

1 0.60–0.79 as moderate, 0.80–0.90 as strong, and values exceeding 0.90 representing almost perfect  
2 agreement [18].

3

#### 4 *Quality of evidence*

5 The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was  
6 used to evaluate the certainty level of evidence for each outcome. This is a systematic and transparent  
7 method used to assess and assign confidence levels to evidence in systematic reviews. It considers the  
8 ROB, inconsistency, indirectness, imprecision, and publication bias. The certainty level of the evidence  
9 was classified as very low, low, moderate, or high [19].

10

#### 11 *Statistical analysis*

12 Due to the use of different types of opioids across studies, the 24 h opioid dose in each study was  
13 converted to morphine milligram equivalents (MME). The mean difference (MD) was calculated for 24  
14 h opioid consumption and pain scores. For dichotomous variables, such as the incidence of side effects  
15 and the use of rescue analgesics, the risk ratio or risk difference was calculated using the Mantel-Haenszel  
16 estimation model. Outcomes with zero events were calculated using the risk difference. A 95% CI was  
17 calculated for all estimates.

18 Considering the variety in study designs, methodologies, and population characteristics, the random-  
19 effects model was applied for the meta-analysis of the effect estimate. To measure heterogeneity, Higgins'  
20  $I^2$ ,  $\tau$  using the DerSimonian-Laird estimator, and prediction interval (PI) was used. If  $\tau$  was 0.0, PI was  
21 not calculated. In cases with extensive heterogeneity [20], sensitivity tests were conducted using the  
22 leave-one-out analysis method. Publication bias was not evaluated in this meta-analysis because the  
23 number of included studies was less than 10.

1 The meta-analysis was conducted using Review Manager (RevMan, [Computer program], Version 5.4,  
2 The Cochrane Collaboration, 2020.) and Comprehensive Meta-Analysis version 2.0 (Englewood, NJ,  
3 USA, 2008). Cohen's kappa for the evaluation of inter-rater reliability was calculated using IBM SPSS  
4 Statistics (IBM Corp.; Released 2017; IBM SPSS Statistics for Windows, Version 25.0: IBM Corp.).

5  
6 **TSA**

7 Conventional meta-analyses are at a risk of random errors when dealing with limited data. TSA reduces  
8 this risk by calculating the required information size (RIS) for a meta-analysis with a threshold for  
9 statistical significance. This methodology provides controls for the potential false-positive and false-  
10 negative findings in meta-analyses [21]. In this study, we performed TSA to determine the RIS and  
11 evaluate the conclusiveness of our results. A cumulative Z curve was constructed using a random effects  
12 model. TSA was conducted to maintain an overall 5% risk of type I error.

13 The TSA results were interpreted by monitoring the cumulative Z curve. If the curve crossed the trial  
14 sequential monitoring boundary or entered the futility area, sufficient evidence existed to accept or reject  
15 the anticipated intervention effect, and further studies were not required. In contrast, if the Z curve failed  
16 to intersect any boundaries and the RIS was not attained, the evidence to form a conclusion was  
17 insufficient, underscoring the necessity for further studies [21].

18 For dichotomous outcomes, the RIS estimation considered the observed proportion of patients with an  
19 outcome in the acetaminophen group (IVA group), a relative risk reduction of 30% in the ibuprofen  
20 group (IVB group), a 5% alpha level, a beta of 20%, and the observed diversity in the trials in the meta-  
21 analysis.

22 For quantitative outcomes, the observed SD was used, along with the MD of the observed SD/3, a 5%  
23 alpha level, a beta of 10%, and the observed diversity from the trials in the meta-analysis. TSA was

1 conducted using the TSA 0.9.5.10 beta software (Copenhagen Trial Unit, Center for Clinical  
2 Intervention Research).  
3

Epub ahead of print

## 1 **Results**

### 2 *Study selection and characteristics*

3 A total of 6461 articles were identified through the initial database search of PubMed (n = 1491),  
4 EMBASE (n = 4293), and the Cochrane Library (n = 677). After removing 1250 duplicates, 5211 articles  
5 were screened. Two reviewers (KM and SH) excluded 5181 studies based on their titles and abstracts.  
6 Thereafter, the full texts of 30 articles were reviewed. Of the remaining 30 articles, 22 were excluded  
7 based on the exclusion criteria. Finally, eight studies (n = 494) were included in the meta-analysis (Fig.  
8 1).

9 The characteristics of the selected studies are presented in Table 1. All the studies were RCTs  
10 conducted on surgical patients under general anesthesia. The types of surgeries varied, including  
11 septorhinoplasty [22], laparoscopic cholecystectomy [12,13,23], laparoscopic bariatric surgery [14],  
12 laparoscopic gastrectomy [24], lumbar disc surgery [25], and percutaneous nephrolithotomy [15]. The  
13 study drugs were injected intravenously, with ibuprofen administered at a dose of 800 mg and  
14 acetaminophen at 1000 mg per administration. In a study by Demirogluk et al. [23], the initial dose of  
15 ibuprofen was 800 mg, and the subsequent dose was 400 mg. In a study by Çelik et al., the study drugs  
16 were administered only once [22], while in others, they were administered multiple times at regular  
17 intervals [12-15,23-25].

18 Postoperatively, opioids were administered via patient-controlled analgesia (PCA) without baseline  
19 infusion. The opioids used in the PCA included tramadol [15,22,23], morphine [14,25], and  
20 fentanyl [12,13,24]. In cases where pain was not adequately relieved by PCA (e.g., VAS 4 or higher),  
21 rescue analgesics were administered. In general, the rescue opioid used differed from the opioid included  
22 in the PCA, except in one study in which both the PCA and rescue opioid were morphine and the amount  
23 of rescue analgesics was included in the 24 h total morphine consumption [25].



1 The pain scores were reported at several time points in each study (Table 1).

### 3 **ROB**

4 For the final eight studies included in the meta-analysis, the ROB was evaluated for each of the four  
5 outcomes (Fig. 2). In the randomization process, four studies [13-15,24] were evaluated as ‘some  
6 concerns’ because of unclear descriptions of the randomization process. In the domain of deviation from  
7 the intended intervention, two studies [13,14] were rated as having ‘some concerns’ because they were  
8 analyzed ‘per protocol’ rather than with ‘intention-to-treat.’ All trials were assessed as having low risk  
9 in the missing outcome data domain. For the measurement of the outcome, one study [13] was rated as  
10 ‘high risk’ on the outcome of side effects, because of the unclear definition of PONV scoring system and  
11 the description of the results. In the selection of the reported results, one study [25] was assessed as ‘high  
12 risk’ for the outcome of pain scores due to the potential distortion of the results. The others were assessed  
13 as low risk.

14 In the ROB assessment, Cohen’s kappa value for the results of the two reviewers was 0.912, indicating  
15 almost perfect agreement.

### 17 **Meta-analysis and TSA**

#### 18 *Twenty-four hours opioid consumption*

19 In a meta-analysis of eight studies [12-15,22-25], 24 h opioid consumption, presented as morphine  
20 milligram equivalent, was significantly lower in the IVB group than in the IVA group (MD: -6.01 mg,  
21 95% CI [-8.60, -3.42],  $P < 0.00001$ ,  $I^2 = 55\%$ ,  $\tau = 2.46$ , 95% PI [-11.82, -0.20]) (Fig. 3). In the sensitivity  
22 analysis excluding one study [12], the heterogeneity disappeared (MD: -5.08 mg, 95% CI [-6.40, -3.76],  
23  $P < 0.00001$ ,  $I^2 = 0\%$ ,  $\tau = 0.00$ ) with maintained direction and significance of the results.

1 TSA indicated that only 41.3% (494 of 1196 patients) of the RIS was accrued. The cumulative Z curve  
2 (blue curve) crossed both the conventional test boundary (dashed red line) and the trial sequential  
3 monitoring boundary (red curve) (Fig. 4A).

4

5 ***Severity of postoperative pain***

6 *VAS at recovery*

7 A meta-analysis comparing five studies [12,15,22-24] showed that pain scores measured at recovery  
8 were lower in the IVB group (MD: -1.42, 95% CI [-2.20, -0.65],  $P = 0.0003$ ,  $I^2 = 82\%$ ,  $\tau = 0.77$ , 95%  
9 PI [-3.57, 0.73]) (Fig. 5A). In the sensitivity test, the heterogeneity disappeared after excluding one  
10 study [12] (MD: -1.04, 95% CI [-1.36, -0.72],  $P < 0.00001$ ,  $I^2 = 0\%$ ,  $\tau = 0.00$ ). Although there was a  
11 reduction in the effect size, the direction and significance of the results remained.

12 TSA indicated that only 15.8% (310 of 1958 patients) of the RIS was accrued. The cumulative Z curve  
13 crossed the conventional test boundary but not the trial sequential monitoring boundary (Supplement).

14 *VAS at 4–6 h postoperatively*

15 Five studies [12,13,15,22-24] assessed pain scores at 4–6 h postoperatively. The IVB group showed  
16 lower pain intensity than the IVA group (MD: -0.83, 95% CI [-1.29, -0.37],  $P = 0.0004$ ,  $I^2 = 65\%$ ,  $\tau =$   
17  $0.45$ , 95% PI [-1.98, 0.32]) (Fig. 5B). In the sensitivity analysis, the exclusion of one study [12] resulted  
18 in an improvement in heterogeneity (MD: -0.62, 95% CI [-0.90, -0.35],  $P < 0.00001$ ,  $I^2 = 0\%$ ,  $\tau = 0.00$ ).  
19 The effect size decreased; however, the direction and statistical significance of the results remained  
20 consistent.

21 TSA indicated that only 37.1% (370 of 997 patients) of the RIS was accrued. The cumulative Z curve  
22 (blue curve) crossed both the conventional test boundary (dashed red line) and the trial sequential  
23 monitoring boundary (red curve) (Fig. 4B).

1 *VAS at 12 h postoperatively*

2 A meta-analysis of five studies [13,15,22-24] demonstrated that the VAS score at 12 h postoperatively  
3 was lower in the IVB group than in the IVA group (MD: -0.38, 95% CI [-0.68, -0.08], P = 0.01, I<sup>2</sup> =  
4 11%, τ = 0.1, 95% PI [-0.70, -0.06]) (Fig. 5C).

5 TSA indicated that only 85.6% (310 of 362 patients) of the RIS was accrued. The cumulative Z curve  
6 (blue curve) crossed both the conventional test boundary (dashed red line) and the trial sequential  
7 monitoring boundary (red curve) (Fig. 4C).

8 *VAS at 24 h postoperatively*

9 A meta-analysis of five studies [12,13,15,22-24] showed no significant difference in the pain scores at  
10 24 h postoperatively between the two groups (MD: -0.26, 95% CI [-0.61, 0.10], P = 0.16, I<sup>2</sup> = 76%, τ =  
11 0.37, 95% PI [-1.22, 0.70]) (Fig. 5D). In the sensitivity analysis, the exclusion of one study [12] resulted  
12 in an improvement in heterogeneity with no significant changes in the results compared to the pooled  
13 analysis (MD: -0.13, 95% CI [-0.32, 0.07], P = 0.20, I<sup>2</sup> = 6%, τ = 0.00).

14 TSA indicated that only 27.1% (370 of 1364 patients) of the RIS was accrued. The cumulative Z curve  
15 did not cross the conventional test boundary (Supplement 2).

16  
17 ***Rescue analgesics***

18 Seven studies [12-15,22-24] were included in the meta-analysis of the effects of both analgesics on the  
19 use of rescue analgesics. The requirement for rescue analgesics was significantly lower in the IVB group  
20 than in the IVA group (RR: 0.40, 95% CI [0.21, 0.74], P = 0.004, I<sup>2</sup> = 39%, τ = 0.41, 95% PI [0.15, 1.09])  
21 (Supplement 2).

22 TSA indicated that only 19.7% (444 of 2256 patients) of the RIS was accrued. The cumulative Z curve  
23 crossed the conventional test boundary but not the trial sequential monitoring boundary (Supplement 2).

1 ***Nausea, vomiting***

2 Four studies [12,22-24] reported the results of postoperative nausea and vomiting separately. Patients in  
3 the IVB group had a significantly lower risk of nausea (RR: 0.49, 95% CI [0.22, 1.08], P = 0.08, I<sup>2</sup> =  
4 25%, τ = 0.38, 95% PI [0.15, 1.63]) and vomiting (RR: 0.49, 95% CI [0.24, 0.99], P = 0.05, I<sup>2</sup> = 0%, τ =  
5 0.00) than patients in the IVA group (Supplement 2).

6 TSA indicated that only 14.5% (260 of 1796 patients) and 8.7% (260 of 2988 patients) of the RIS was  
7 accrued for nausea and vomiting, respectively. The cumulative Z curves for nausea and vomiting did not  
8 cross the conventional test boundaries (Supplement 2).

9

10 ***Other side effects***

11 Pruritus was reported in seven studies [12,14,15,22-25], and the meta-analysis showed no significance  
12 (Risk Difference: -0.02, 95% CI [-0.07, 0.03], P = 0.42, I<sup>2</sup> = 58%, τ = 0.1, 95% PI [-0.26, 0.22])  
13 (Supplement 2). TSA indicated that only 13.1% (434 of 3302 patients) of the RIS was accrued. The  
14 cumulative Z curve did not cross the conventional test boundary (Supplement 2).

15 Dyspepsia was investigated in three studies [12,14,22], and the meta-analysis revealed no significant  
16 difference between the two groups (Risk Difference: -0.03, 95% CI [-0.12, 0.06], P = 0.52, I<sup>2</sup> = 67%, τ  
17 = 0.14, 95% PI [-0.63, 0.58]) (Supplement 2). TSA indicated that only 4.8% (260 of 5445 patients) of  
18 the RIS was accrued. The trial sequential monitoring boundary was ignored owing to insufficient  
19 information. The cumulative Z curve did not cross the conventional test boundary (Supplement 2).

20 As for other side effects, despite being evaluated in several studies, the reported incidence frequently  
21 remained zero. Respiratory depression assessed in four studies [12,14,22,23] showed zero incidence.  
22 Constipation assessed in two studies [12,22] showed zero incidence. Confusion/sedation, evaluated in  
23 three studies [12,14,22], showed an incidence of 0 out of 35 in the IVB group and 2 out of 39 in the IVA

1 group in only one study [14]. Urinary retention, observed in four studies [12,22,23,25], was reported in  
2 only one study [25] with an incidence of 2 out of 25 in the IVB group and 1 out of 25 in the IVA group.  
3 Bleeding was assessed in three studies [12,22,23], with one study [22] reporting an incidence of 2 out of  
4 50 in the IVB group and 1 out of 50 in the IVA group. Headache, evaluated in two studies [14,23],  
5 showed an incidence of 7 out of 35 in the IVB group and 7 out of 39 in the IVA group in a single  
6 study [14]. Meta-analysis of confusion/sedation, urinary retention, bleeding, and headache showed no  
7 significant results (Supplement 2).

8

### 9 ***Certainty level of evidence from GRADE***

10 The quality of evidence from this meta-analysis for each outcome is presented in a summary of findings  
11 table (Table 2). The certainty level for pain scores at 12 h was assessed as high. The 24 h opioid  
12 consumption and vomiting was considered moderate. However, the certainty levels for pain scores at 4–  
13 6 and 24 h, rescue analgesics, and nausea were low.

## 1 Discussion

2 Although the roles of IV ibuprofen and acetaminophen as postoperative adjuvant analgesics are well  
3 established, there is insufficient evidence regarding the comparative efficacy of these two drugs for  
4 postoperative pain after general anesthesia. This meta-analysis confirmed that postoperative opioid  
5 consumption at 24 h and pain intensity up to 12 h postoperatively were significantly lower with IV  
6 ibuprofen than with acetaminophen, and this statistical significance was maintained with TSA. However,  
7 the TSA revealed that the sample size of the meta-analysis was insufficient to assess the effects of the  
8 study drugs on pain scores at 24 h postoperatively, rescue analgesic requirements, and side effects.

9 The results of this study regarding the effect on opioid consumption and pain scores are in line with  
10 those of a recent meta-analysis by Zhou et al., who evaluated the analgesic and antipyretic effects of IV  
11 ibuprofen compared with those of placebo and acetaminophen [26]. However, the studies included by  
12 Zhou et al. were more heterogeneous than ours; the anesthetic types varied from local anesthesia to  
13 regional and general anesthesia, and endoscopic procedures were also included. Furthermore, the effect  
14 on opioid consumption has not been adequately assessed, as the opioid-sparing effects of ibuprofen and  
15 acetaminophen were evaluated for each type of opioid (tramadol, fentanyl, and morphine). We consider  
16 it more reasonable to comprehensively analyze all opioids together based on morphine equivalent doses,  
17 as in our study.

18 In our study, the 24 h opioid consumption was lower in the IVB group by approximately 6 mg in MME  
19 (MD: -6.01,  $P < 0.00001$ ) than in the IVA group. Despite the reduced amount of opioids, the  
20 postoperative pain scores were significantly lower in the IVB group for up to 12 h postoperatively,  
21 suggesting the superiority of ibuprofen over acetaminophen for postoperative pain relief. Furthermore,  
22 the need for rescue analgesics was significantly lower in the IVB group, although these results were not  
23 confirmed in TSA.

1 The MD in pain scores between IVB and IVA, on a scale of 10 points, showed a decreasing trend over  
2 time, with  $-0.83$  points at 4–6 h,  $-0.38$  points at 12 h, and no significant difference between the two  
3 groups at 24 h. Although the effects on pain intensity at 24 h postoperatively are inconclusive based on  
4 the TSA results, the effect appears to diminish over time, and this may be associated with the decreasing  
5 intensity of postoperative pain over time.

6 As the opioid dose was significantly lower in the IVB group, opioid-related side effects, such as nausea  
7 and vomiting, could be reduced in this group [27]. However, this finding was not confirmed by the  
8 present meta-analysis. Considering their pharmacological effects, the incidence of gastrointestinal  
9 problems and bleeding tendencies may differ between ibuprofen and acetaminophen. Nevertheless, it has  
10 been suggested that ibuprofen does not increase these side effects [28,29], and the frequency of adverse  
11 effects was very low in our study. Despite the small sample size in this meta-analysis, ibuprofen did not  
12 appear to significantly increase gastrointestinal or hemorrhagic complications in a postoperative setting.

13 This study had some limitations. First, the meta-analysis of opioid consumption and pain scores  
14 showed moderate-to-substantial heterogeneity, except for pain scores at 12 h. Because the type of surgery  
15 can influence postoperative opioid consumption [30], various types of surgeries could contribute to this  
16 heterogeneity. Moreover, variations in the timing of the administration of the study drugs or the types of  
17 opioids used could be potential causes. Interestingly, in the sensitivity analysis, excluding the study by  
18 Ekinici et al. [12], the heterogeneity significantly decreased. Upon review, the study by Ekinici et al. [12]  
19 did not seem to be significantly different compared to other studies in terms of study design, demographic  
20 characteristics, dosing frequency, and intervals, making it difficult to identify the specific cause of  
21 heterogeneity. If there was one minor difference compared to other studies, the MD in the VAS scores  
22 between the IVB and IVA groups was reported to be particularly large. Second, due to the limited number  
23 of studies included in this meta-analysis and variations in administration timing across studies, it was not

1 possible to compare the effects of the study drugs based on administration timing, such as preoperative,  
2 intraoperative, or postoperative administration. Third, various types of surgery were included in this  
3 meta-analysis. According to a network meta-analysis by Carter et al. [31], the effects of ibuprofen and  
4 acetaminophen on the reduction of postoperative pain intensity can vary depending on the type of surgery.  
5 However, in the study by Carter et al., the number of included studies was too small to draw conclusions.

6 In summary, the perioperative administration of IV ibuprofen demonstrated a superior analgesic effect  
7 compared with that of IV acetaminophen up to 12 h postoperatively, leading to a reduction in 24 h opioid  
8 consumption. Further studies are required to assess the effects on pain intensity beyond 12 h, rescue  
9 analgesic requirements, and side effects. We anticipate that ibuprofen may be a beneficial adjuvant  
10 analgesic for postoperative pain.

Epub ahead of Print



## References

1. Kehlet H, Holte K. Effect of postoperative analgesia on surgical outcome. *Br J Anaesth* 2001; 87: 62-72.
2. Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. *Anesth Analg* 2017; 125: 1733-40.
3. Kumar K, Kirksey MA, Duong S, Wu CL. A review of opioid-sparing modalities in perioperative pain management: methods to decrease opioid use postoperatively. *Anesth Analg* 2017; 125: 1749-60.
4. Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. *Curr Opin Anaesthesiol* 2009; 22: 588-93.
5. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain* 2016; 17: 131-57.
6. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. *Anesthesiology* 2012; 116: 248-73.
7. Smith HS. Perioperative intravenous acetaminophen and NSAIDs. *Pain Med* 2011; 12: 961-81.
8. Cashman JN. The mechanisms of action of NSAIDs in analgesia. *Drugs* 1996; 52(Suppl 5): 13-23.

9. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. *Am J Med* 1998; 104: 2S-8S.
10. Jahr JS, Lee VK. Intravenous acetaminophen. *Anesthesiol Clin* 2010; 28: 619-45.
11. Smith HS, Voss B. Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever. *Drugs* 2012; 72: 327-37.
12. Ekinçi M, Ciftçi B, Celik EC, Köse EA, Karakaya MA, Ozdenkaya Y. A randomized, placebo-controlled, double-blind study that evaluates efficacy of intravenous ibuprofen and acetaminophen for postoperative pain treatment following laparoscopic cholecystectomy surgery. *J Gastrointest Surg* 2020; 24: 780-5.
13. Mohammadian Erdi A, Arabzadeh A, Isazadehfar K, Masoumzadeh M, Bahadoram M. Comparing the efficacy and side effects of intravenous ibuprofen and acetaminophen in pain control following laparoscopic cholecystectomy. *World J Plast Surg* 2022; 11: 117-24.
14. Erdogan Kayhan G, Sanli M, Ozgul U, Kirteke R, Yologlu S. Comparison of intravenous ibuprofen and acetaminophen for postoperative multimodal pain management in bariatric surgery: a randomized controlled trial. *J Clin Anesth* 2018; 50: 5-11.
15. Ucar M, Erdogan MA, Sanlı M, Colak YZ, Aydogan MS, Yucel A, et al. Efficacy of intravenous ibuprofen and intravenous paracetamol in multimodal pain management of postoperative pain after percutaneous nephrolithotomy. *J Perianesth Nurs* 2022; 37: 540-4.
16. McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. *Stat Methods Med Res* 2020; 29: 2520-37.
17. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; 366: 14898.

18. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)* 2012; 22: 276-82.
19. Granholm A, Alhazzani W, Møller MH. Use of the GRADE approach in systematic reviews and guidelines. *Br J Anaesth* 2019; 123: 554-9.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557-60.
21. Kang H. Trial sequential analysis: novel approach for meta-analysis. *Anesth Pain Med (Seoul)* 2021; 16: 138-50.
22. Çelik EC, Kara D, Koc E, Yayik AM. The comparison of single-dose preemptive intravenous ibuprofen and paracetamol on postoperative pain scores and opioid consumption after open septorhinoplasty: a randomized controlled study. *Eur Arch Otorhinolaryngol* 2018; 275: 2259-63.
23. Demiroglu Ö, Abitağaoğlu S, Göçmen DK, Özcabi Y, Ari DE. Comparison of analgesic effects of paracetamol and ibuprofen after laparoscopic cholecystectomy. *Turkiye Klinikleri J Med Sci* 2019; 39: 278-84.
24. Ciftci B, Ekinci M, Celik EC, Kaciroglu A, Karakaya MA, Demiraran Y, et al. Comparison of intravenous ibuprofen and paracetamol for postoperative pain management after laparoscopic sleeve gastrectomy. A randomized controlled study. *Obes Surg* 2019; 29: 765-70.
25. Akbas S, Ozkan AS, Durak MA, Yologlu S. Efficacy of intravenous paracetamol and ibuprofen on postoperative pain and morphine consumption in lumbar disc surgery: prospective, randomized, double-blind, placebo-controlled clinical trial. *Neurochirurgie* 2021; 67: 533-9.

26. Zhou P, Chen L, Wang E, He L, Tian S, Zhai S. Intravenous ibuprofen in postoperative pain and fever management in adults: a systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res Perspect* 2023; 11: e01123.
27. Roberts GW, Bekker TB, Carlsen HH, Moffatt CH, Slattery PJ, McClure AF. Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner. *Anesth Analg* 2005; 101: 1343-8.
28. Bjarnason I. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. *J R Soc Med* 2007; 100(Suppl 48): 11-4.
29. Kelley BP, Bennett KG, Chung KC, Kozlow JH. Ibuprofen may not increase bleeding risk in plastic surgery: a systematic review and meta-analysis. *Plast Reconstr Surg* 2016; 137: 1309-16.
30. Kim KM, Kim HS, Lim SH, Cheong SH, Choi EJ, Kang H, et al. Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. *Int J Clin Pharmacol Ther* 2013; 51: 383-92.
31. Carter JA, Black LK, Sharma D, Bhagnani T, Jahr JS. Efficacy of non-opioid analgesics to control postoperative pain: a network meta-analysis. *BMC Anesthesiol* 2020; 20: 272.

**Table 1.** Characteristics of the included studies

Study	Type of surgery	Interventions (No. of patients)	Timing of administration	Postoperative outcomes		
				Post-op opioid used in PCA	Post-op pain measurement (VAS)	Rescue analgesics
Çelik 2018 [22]	Septorhinoplasty	IVB 800 mg (50) IVA 1 g (50)	Before induction	Tramadol	At recovery, 1, 6, 12, 24 h	Meperidine 25 mg
Erdogan Kayhan 2018 [14]	Laparoscopic bariatric surgery	IVB 800 mg (40) IVA 1 g (40)	Before skin closure, q 6 h for postop 24 h	Morphine	Between 1 and 24, 6 and 24, 12 and 24 h	Tramadol 0.5 mg/kg
Ciftci 2019 [24]	Laparoscopic sleeve gastrectomy	IVB 800 mg (30) IVA 1 g (30)	After intubation, q 8 h for postop 24 h	Fentanyl	At recovery, 2, 4, 8, 12, 24 h	Meperidine 0.25 mg/kg
Demirogluk 2019 [23]	Laparoscopic cholecystectomy	IVB 800 mg → 400 mg (20) IVA 1 g (20)	After creating a pneumoperitoneum, q 6 h for postop 24 h	Tramadol	At recovery, 6, 12, 24 h	Meperidine 20 mg

Ekinci 2020 [12]	Laparoscopic cholecystectomy	IVB 800 mg (30) IVA 1 g (30)	30 min preop, q 8 h for postop 24 h	Fentanyl	At recovery, 1, 2, 4, 8, 16, 24 h	Meperidine 0.25 mg/kg
Akbas 2021 [25]	Lumbar disc surgery	IVB 800 mg (25) IVA 1 g (25)	At wound closure, q 6 h for postop 24 h	Morphine	Between 1 and 24, 6 and 24, 12 and 24 h	Morphine 2 mg → included in 24 h total morphine consumption
Mohammadian Erdi 2022 [13]	Laparoscopic cholecystectomy	IVB 800 mg (30) IVA 1 g (30)	Intraop, postop 8 h, 16 h	Fentanyl	At 6, 12, 18, 24 h	Meperidine 0.5 mg/kg
Ucar 2022 [15]	Percutaneous nephrolithotomy	IVB 800 mg (25) IVA 1 g (25)	Before skin closure, q 6 h for postop 24 h	Tramadol	At 0.5, 2, 4, 6, 12, 24 h	No information about rescue analgesics, but the incidence is shown.

IVA: intravenous acetaminophen, IVB: intravenous ibuprofen, PCA: patient-controlled analgesia, VAS: visual analog scale

**Table 2.** Summary of findings

Outcomes	Anticipated effects* (95% CI)	absolute	Relative effect (95% CI)	No. of participants	ROB	Inconsistency	Indirectness	Imprecision	Publication bias	Certainty of the evidence (GRADE)
	Risk with IV acetaminophen	Risk with IV ibuprofen								
24 h opioid consumption (morphine equivalent)	The mean 24 h opioid consumption: 37.97 mg	MD: –6.01 mg	–8.6, –3.42)	494 (8 RCTs)	Not serious	Serious	Not serious	Not serious	Undetected	⊕⊕⊕○ Moderate <sup>†</sup>
VAS at 4–6 h	The mean VAS:	MD: –0.83	–	370 (6 RCTs)	Not serious	Serious	Not serious	Serious	Undetected	⊕⊕○○ Low <sup>†,‡</sup>

	3.29			(-1.29, -							
				0.37)							
VAS at 12 h	The	mean	MD:	-	310	Not serious	Not Serious	Not serious	Not serious	Undetected	⊕⊕⊕⊕
	VAS:				(5 RCTs)						High
	2.60			(-0.64, -							
				0.1)							
VAS at 24 h	The	mean	MD	-	370	Not serious	Serious	Not serious	Serious	Undetected	⊕⊕○○
	VAS:				(6 RCTs)						Low <sup>†,§</sup>
	1.22			(-0.61,							
				0.1)							
Rescue	263 per 1,000	108	per RR	0.41	444	Not serious	Serious	Not serious	Serious	Undetected	⊕⊕○○
analgesic		1,000	(0.28	to	(7 RCTs)						Low <sup>†,§</sup>
		(74	to	0.62)							
		163)									



Nausea	223 per 1,000	107	per RR	0.48	260	Not serious	Serious	Not serious	Serious	Undetected	⊕⊕○○	Low <sup>†,§</sup>
		1,000	(0.27	to	(4 RCTs)							
		(60	to	0.87)								
		194)										
Vomiting	169 per 1,000	80	per RR	0.47	260	Not serious	Not serious	Not serious	Serious	Undetected	⊕⊕⊕○	Moderate <sup>§</sup>
		1,000	(0.23	to	(4 RCTs)							
		(39	to	0.93)								
		157)										

---

Rescue analgesic, nausea, and vomiting were evaluated for postoperative 24 h.

CI: confidence interval, GRADE: Grading of Recommendations, Assessment, Development, and Evaluations, IV: intravenous, MD: mean difference, PI: prediction interval, RCTs: randomized controlled trials, ROB: risk of bias, RR: risk ratio, VAS: visual analog scale.

#### **GRADE Working Group grades of evidence**

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

### **Explanations**


\*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

† The 95% PI is significantly wider than the 95% CI.


‡ The 95% PI crosses the line of identity in contrast to the 95% CI.

§ The optimal information size criterion is not met.

## Figure legends




**Fig. 1.** Flow diagram of study selection




**Fig. 2.** Risk of bias

(A) 24 h opioid consumption, (B) Postoperative pain scores, (C) Use of rescue analgesics, (D) Side effects




**Fig. 3.** Forest plot: effect of ibuprofen and acetaminophen on 24 h opioid consumption.



**Fig. 4.** Trial sequential analysis

(A) 24 h opioid consumption, (B) VAS at 4–6 h postoperatively, (C) VAS at 12 h postoperatively.

VAS: visual analog scale.



**Fig. 5.** Forest plot: effect of ibuprofen and acetaminophen on postoperative pain scores. (A) VAS at recovery, (B) VAS at 4–6 h postoperatively, (C) VAS at 12 h postoperatively, (D) VAS at 24 h postoperatively. VAS: visual analog scale.